Mylan NV

Mylan NV is a generic and specialty pharmaceutical company. The Company offers one of the industry's broadest and highest quality product portfolios, a robust product pipeline and a global commercial footprint through operations in more than 90 countries. Mylan NV was established in 1961 and is headquartered in Hertfordshire, England.

Company Summary

SECTOR

Revenue

Employees

35,000

Established

1961

Public

NASDAQ: MYL

According to our data here at Mergr, Mylan NV has acquired 9 companies, including 4 in the last 5 years. A total of 2 acquisitions came from private equity firms.

Mylan NV’s largest acquisition to date was in 2007, when it acquired Merck Generics for $5.5B. Mylan NV has acquired in 3 different US states, and 4 countries. The Company’s most targeted sectors include life science (67%) and medical products (34%).

When analyzing the life science sector as a whole, according to Mergr, in the last 3 years, there are 410 life science companies that have made at least 1 acquisition, 23 have acquired at least 5 companies, and 3 have acquired more than 10 companies. The most prolific strategic life science acquirer over the past 3 years is Eurofins Scientific SA, with 25 acquisitions. The most prolific private equity acquirer in the life science sector over the past 3 years is Ampersand Capital Partners with 4 platform acquisitions.

Join Mergr and gain access to Mylan NV’s M&A summary, the M&A summaries of companies just like it, as well as recent M&A activity in the life science sector.